

Efficacy Of Remibrutinib Versus Dupilumab In Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM)

G. Yosipovitch, G. Mosnaim, C-E. Ortmann, N. Griswold, J. Mast, El-D. Martzloff, J. Rodrigues, J. Hawkes

Please click [HERE](#) to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this [LINK](#) to access the abstract after November 10, 2025, once it is available on the congress website

ACAAI 2025, American College of Allergy, Asthma & Immunology. (ACAAI), November 6–10, 2025